# John W. Eikelboom

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/john-w-eikelboom/

## Facts

| Field | Value |
| --- | --- |
| Citations | 96,896 |
| Field | Atrial Fibrillation Management and Outcomes |
| h-index | 132 |
| i10-index | 610 |
| Last Known Institution | Population Health Research Institute |
| OpenAlex ID | https://openalex.org/A5087630518 |
| ORCID iD | https://orcid.org/0000-0003-4126-1285 |
| Works | 1,118 |

## Researcher papers

Showing 12 of 18.

- [Dabigatran versus Warfarin in Patients with Atrial Fibrillation](https://scholariq.org/papers/dabigatran-versus-warfarin-in-patients-with-atrial-fibrillation/)
- [Standardized Bleeding Definitions for Cardiovascular Clinical Trials](https://scholariq.org/papers/standardized-bleeding-definitions-for-cardiovascular-clinical-trials/)
- [COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up](https://scholariq.org/papers/covid-19-and-thrombotic-or-thromboembolic-disease-implications-for-prevention/)
- [Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-stable-cardiovascular-disease/)
- [Colchicine in Patients with Chronic Coronary Disease](https://scholariq.org/papers/colchicine-in-patients-with-chronic-coronary-disease/)
- [Idarucizumab for Dabigatran Reversal](https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal/)
- [Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes](https://scholariq.org/papers/adverse-impact-of-bleeding-on-prognosis-in-patients-with-acute-coronary/)
- [Idarucizumab for Dabigatran Reversal — Full Cohort Analysis](https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal-full-cohort-analysis/)
- [Myocardial Injury after Noncardiac Surgery](https://scholariq.org/papers/myocardial-injury-after-noncardiac-surgery/)
- [Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-patients-with-stable-peripheral-or/)
- [Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention](https://scholariq.org/papers/defining-high-bleeding-risk-in-patients-undergoing-percutaneous-coronary-2/)
- [Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-patients-with-stable-coronary-artery/)

## Researcher topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management-2/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Cardiac Arrhythmias and Treatments](https://scholariq.org/topics/cardiac-arrhythmias-and-treatments/)

## Researcher university

- [Population Health Research Institute](https://scholariq.org/institutions/population-health-research-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.